This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
Kidney Cancer
RadiCal
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
FORT
NRG-GU 0101
Masofaniten (Oral EPI-7386)
RTIRE
SHORTER
SPLASH
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Suprapubic Catheter
Diane K. Newman, DNP FAAN BCB-PMD
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
AMA Interim 2023
SUO 2023
ESMO 2023
IBCN 2023
ASTRO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2021
ASCO GU 2021
Prostate Cancer
Bladder Cancer
Kidney Cancer
Penile, Urethral, Testicular, and Adrenal Cancers
Press Releases
ASCO GU 2021 Kidney Cancer
Viewing 1-20 of 38 articles
ASCO GU 2021: The CLEAR Study of Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib and the SWOG 1500 Trial of Sunitinib, Cabozantinib, Crizotinib, and Savolitinib in Advanced Kidney Cancer: Discussion
ASCO GU 2021: MK-6482 in Patients with Clear Cell Renal Cell Carcinoma: Discussion
ASCO GU 2021: The Oral HIF-2 α Inhibitor MK-6482 in Patients with Advanced Clear Cell Renal Cell Carcinoma (RCC): Updated Follow-up of a Phase I/II Study
ASCO GU 2021: Phase 3 Trial of Lenvatinib plus Pembrolizumab or Everolimus Versus Sunitinib Monotherapy as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (CLEAR Study)
ASCO GU 2021: Patterns of Progression in Patients Treated with Nivolumab plus Ipilimumab (NIVO+IPI) Versus Sunitinib (SUN) for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
ASCO GU 2021: Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Radiology “Write This Down” - What Do Nonradiologists Need to Know
ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Quality of Life Corner
ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Cure the Cancer or Avoid Dialysis? Helping Decide
ASCO GU 2021: Bench to Bedside: Critical Pathways in Renal Cell Carcinoma – Peri-Operative Morbidity and Mortality in a Modern Series of Patients Treated with Cytoreductive Nephrectomy at Five Centers
ASCO GU 2021: Best of the Journals: Renal Cell Carcinoma – Surgery
ASCO GU 2021: Best of the Journals: Renal Cell Carcinoma – Pathology
ASCO GU 2021: Best of Journals: Renal Cell Carcinoma – Medical Oncology
ASCO GU 2021: Outcomes of First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the International mRCC Database Consortium
ASCO GU 2021: Stereotactic Radiotherapy and Pembrolizumab for Oligometastatic Renal Tumors: The RAPPORT Trial
ASCO GU 2021: Angiogenic and T-Effector Subgroups Identified by Gene Expression Profiling and Propensity for PBRM1 and BAP1 Alterations in Clear Cell Renal Cell Carcinoma
ASCO GU 2021: TIVO-3: Tivozanib in Patients with Advanced Renal Cell Carcinoma Who Have Progressed After Treatment with Axitinib
ASCO GU 2021: NAXIVA: A Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumor Thrombus in Clear Cell Renal Cell Cancer with Venous Invasion
ASCO GU 2021: Sarcomatoid Versus Clear Cell RCC: A Comparative Comprehensive Genomic Profiling Study
ASCO GU 2021: Illustration of Temporal Evolution in Patients with mRCC Using Both ctDNA and Tissue-Based Genomic Data
1
2
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free